A Phase 3 Randomized Study of Selumetinib (IND # 77782) Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low Grade Glioma (LGG)
For more information about the trial above please contact the study team:
Principal Investigator, Jacqueline Kraveka, at email@example.com.
Study Coordinator, Jared Hortman, at firstname.lastname@example.org.
Trial opened at the following institutions: Medical University of South Carolina